Sophie Shulman

20 stories about Sophie Shulman
מטה טבע כפר סבא

Teva surpasses expectations in Q4 but sets cautious outlook for 2025

29.01.25|Sophie Shulman
Despite a strong finish to the year, Teva forecasts lower-than-expected earnings and revenue growth for 2025.
מייסדי באז Baz מימין גיא איזנקוט ו נמרוד קור

From Palo Alto exit to personal loss: Guy Eisenkot's journey to launching Baz

29.01.25|Sophie Shulman
The CEO of the new AI startup, Baz, channels grief into tech innovation following the death of his brother in Gaza. 
בינה מלאכותית AI DeepSeek דיפסיק 1

DeepSeek’s success sparks a new chapter in U.S.-China AI rivalry

28.01.25|Sophie Shulman
How Chinese engineers turned sanctions into an opportunity for global disruption.
בינה מלאכותית AI דיפסיק DeepSeek

Trillion-dollar tumble: How China’s DeepSeek app rattled Wall Street

28.01.25|Sophie Shulman
The Nasdaq plunged as DeepSeek’s low-cost AI questions Nvidia’s stranglehold on AI chips.
מנכ"ל אינטל פט גלסינגר 2 אפריל 2024

Former Intel CEO Pat Gelsinger reinvents himself as an angel investor in AI startup Fractile

22.01.25|Sophie Shulman
The British startup, backed by $15M in funding, aims to revolutionize low-cost AI inferencing with innovative chip technology.
מנכ"ל אוסטו לשעבר אניוויז'ן אבי גולן 2021

What went wrong at AnyVision? Lessons from a $352M flameout

21.01.25|Sophie Shulman
Big investors, bold promises, and why the Israeli AI startup struggled to commercialize.
מנכ"ל אוסטו לשעבר אניוויז'ן אבי גולן 2021

Facial recognition firm Oosto, formerly AnyVision, sold for $125M after raising $352M

20.01.25|Sophie Shulman
Controversy and market challenges brought the Israeli startup’s ambitions to a halt and resulted in a sale to parking lot company Metropolis.
חיילים ביחידה 8200

Eight trends that defined Israeli tech in 2024

31.12.24|Sophie Shulman, Meir Orbach
A year of cyber milestones, wartime innovation, and shifting investment dynamics.
קו הרקיע של מנהטן ניו יורק

TechAir flights from Israel to New York take off January 21

26.12.24|Sophie Shulman
Presale offers fares starting at $1,550 as High-Tech Forum secures Airbus A330-900 for new service.
רון יקותיאל קלטורה ועידת Mind The Tech

Kaltura CEO: "Just like a missile hit our office, a missile hit us with the IPO"

24.12.24|Sophie Shulman
Despite devastating events and financial struggles, CEO Ron Yekutiel remains focused on the company's future. 
עובדי windward ווינדוורד

Windward acquired for $270M by FTV Capital, doubling its IPO valuation

24.12.24|Sophie Shulman
The Israeli maritime analytics company will be delisted from the stock exchange, marking a premium exit for shareholders.
מוסף שבועי 19.1.23 עומר כילף מנכ"ל אינוויז

Innoviz secures $80M in development funding as cash reserves run thin

23.12.24|Sophie Shulman
The automotive sensor company will receive critical non-recurring engineering payments through 2027 amid revenue struggles.
מייסדי וויז, מימין לשמאל: רועי רזניק , עמי לוטבק , אסף רפפורט ו ינון קוסטיקה

Israeli high-tech funding rounds hit five-year low despite $9.7B raised in 2024

23.12.24|Sophie Shulman
Cybersecurity dominates investments, accounting for 42% of total funding, while new startups struggle to emerge.
מייסדי מורנינג מימין ליאור וילצ'ינסקי (מנכ"לית) ו רמי גבאי (סמנכ"ל טכנולוגיות)

Israeli fintech Morning acquired for $150 million by Italy's TeamSystem

22.12.24|Sophie Shulman
The purchase of the Israeli company, known for its "Green Invoice" system, will especially benefit founders Lior Wilczynski and Rami Gabai, as well as the Fortissimo fund, which invested in the company three years ago.
מימין: אהוד שנאורסון , אהוד ברק , עידן נוריק , ליעד אברהם ו מיכאל בוגודלוב פאראגון

Can a tweet derail a $900 million cyber-tech deal?

22.12.24|Sophie Shulman
Paragon’s sale sparks debates over regulation, judiciary independence, and political influence.
מימין אהוד שניאורסון אהוד ברק חברת פאראגון

Paragon’s $900M sale in limbo as Defense Ministry steps in

19.12.24|Sophie Shulman
“Contrary to reports, the Ministry of Defense did not approve the sale of Paragon. The Ministry is examining the sale procedure and its implications,” the Ministry said in a statement. 
 ריצרד פרנסיס  נשיא ו מנכל חברה חברת טב

Teva’s 10-year turnaround takes shape with stunning trial results

18.12.24|Sophie Shulman
Duvakitug signals a brighter future for the Israeli pharma giant. 
מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Teva shares jump as its most promising drug shows exceptional trial results

17.12.24|Sophie Shulman
Duvakitug, designed to treat colitis and Crohn’s disease, exceeded expectations and positions Teva to compete in the $28 billion global market for inflammatory bowel disease treatments.